Study Evaluating ReFacto in Hemophilia A
Launched by WYETH IS NOW A WHOLLY OWNED SUBSIDIARY OF PFIZER · Jun 6, 2002
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients who were or are enrolled in Study CTN 93-R833-0XX/C9741-28, and have been treated with ReFacto® during this study are eligible for participation.
- • The patient (or legal guardian) must be willing to give written informed consent before any study-related procedures are performed.
- • A blood sample will be collected from each patient for the purpose of this study and will be analyzed at one or both of the designated central laboratories.
- Exclusion Criteria:
- • Any condition which, in the investigator's opinion, places the patient at undue risk.
About Wyeth Is Now A Wholly Owned Subsidiary Of Pfizer
Wyeth, now a wholly owned subsidiary of Pfizer, is a global biopharmaceutical company dedicated to advancing healthcare through innovative research and development. With a strong legacy in the pharmaceutical industry, Wyeth focuses on discovering and delivering medicines that address significant medical needs across various therapeutic areas, including vaccines, biologics, and specialty pharmaceuticals. Leveraging Pfizer's extensive resources and expertise, Wyeth continues to drive scientific advancement and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Medical Monitor, MD
Study Director
Wyeth is now a wholly owned subsidiary of Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials